Symphony Environmental Reports Higher FY-2025 Revenue and Confident Start to 2026 with Projected First Half Profit

The one-off charges are not tiny, though. Symphony is taking £500,000 of strategic costs, a £468,000 impairment provision tied to antimicrobial product development, and £107,000 of other investment provisions. Add those together and you can see why the reported bottom line took such a hit.

Middle East strategy changes look like the main operational driver

The company explicitly says the improvement in FY-2025 revenue came from management-driven strategic change in its Middle East operations. That is encouraging because it points to an active fix rather than a lucky bounce.

Even better, Symphony says margins are improving as well. In plain English, margins tell you how much profit is left after direct costs, and improving margins usually mean the company is making better-quality sales or operating more efficiently. Management credits both operational leverage and the strategic work done during FY-2025, particularly in the Middle East.

That is a positive sign for investors because a small rise in revenue can have a bigger effect on profit once the cost base is under better control.

Strong start to 2026: positive EBITDA in Q1 and a targeted H1 profit

This is the part of the update that really matters. Symphony says the first four months of 2026 have improved materially, with revenue running more than 10 per cent ahead of the same period last year.

More than that, the group delivered positive EBITDA in Q1-2026. EBITDA is earnings before interest, tax, depreciation and amortisation, and while it is not the same as cash profit, it is still a useful sign that the core business has moved into better shape.

The standout line is the expectation of a net profit for H1-2026. That is not just management saying conditions are stable. It is management saying the business could move into actual reported profit in the first half of the year.

For a smaller AIM-listed company that has been loss-making, that changes the tone. If delivered, it would suggest the turnaround is becoming visible in reported numbers rather than staying trapped in presentations and strategy statements.

Central America is helping, and order visibility appears to be improving

Symphony says confirmed orders have been received across all principal markets, particularly Central America. That is helpful because it suggests growth is not coming from a single one-off customer or territory alone.

The board also says it is encouraged by the visibility and quality of the pipeline. A pipeline is basically the list of expected future business opportunities and orders. It is not the same as booked revenue, but stronger order visibility usually reduces uncertainty.

There is one caveat. Shipment timing remains subject to customer scheduling and normal operational factors, so the exact phasing of revenue is not guaranteed. That is a sensible warning and one investors should not ignore.

What looks good, and what still looks weak in Symphony Environmental’s update

The positives

• FY-2025 revenue is now expected to be higher than previously guided at approximately £5.7 million.
• Q1-2026 delivered positive EBITDA, compared with a loss in the same period last year.
• Revenue in the first four months of 2026 is running more than 10 per cent ahead year on year.
• The board expects a net profit for H1-2026.
• Margins are improving, which usually matters more than chasing low-quality volume.

The negatives

• The expected FY-2025 net loss is still heavy at £2.5 million.
• The antimicrobial products have triggered a £468,000 impairment provision after extended South American trials and commercial evaluation.
• Shipment timing remains uncertain, so some revenue could move between periods.
• The geopolitical situation in the Middle East is still being monitored, even though it has not had a material adverse effect so far.

My view: this is a better quality update than the FY-2025 loss suggests

I think this announcement is more positive than negative. Not because FY-2025 was pretty – it was not – but because the company appears to be exiting the year in much better shape than it entered it.

The market often cares more about direction of travel than the rear-view mirror. Here, the rear-view mirror shows a larger net loss, but the forward view shows improving margins, positive Q1 EBITDA, revenue growth of more than 10 per cent, and a stated expectation of H1 net profit.

That said, investors should stay disciplined. This is still a pre-close update and the FY-2025 numbers are subject to audit. The company has also not disclosed cash, debt, or detailed balance sheet figures in this announcement, so we do not yet have the full financial picture.

There is also a question around the antimicrobial side of the business. The impairment linked to extended customer trials in South America tells you that commercialisation has been slower than hoped. That does not mean the opportunity has disappeared, but it does mean investors should be careful about assigning too much value to that segment until sales are clearer.

What retail investors should watch next in Symphony Environmental shares

The next major checkpoint will be the preliminary FY-2025 results, which the board expects to announce in the latter half of May. Investors should focus on a few things when those numbers land.

• Whether revenue does indeed come in at around £5.7 million.
• Whether the adjusted LBITDA loss is around £0.9 million as guided.
• Cash and funding details, which were not disclosed in this update.
• Evidence that Q1 momentum carried into Q2.
• Any further detail behind the expected H1-2026 net profit.

In short, Symphony Environmental has served up a mixed FY-2025 picture but a notably stronger 2026 outlook. If the H1 profit lands as guided, this update could end up being remembered as the point where the story started to turn from restructuring to delivery.